Bioavailability Heathy VolunteersPhase 3NCT07046975
Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone
A Phase 3 study testing Torsemide and Spironolactone tablet and Torsemide Tablets and Spironolactone Tablets in people with Bioavailability Heathy Volunteers, run by Sarfez Pharmaceuticals, Inc. at 1 site in United States.
Trial summary
To study intrasubject variability and steady-state pharmacokinetics of multiple-doses of Extended Release Torsemide and Spironolactone Fixed Dose Combination (FDC) tablets given together in healthy adult subjects. Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Bioavailability Heathy Volunteers
- What is being tested?
- Torsemide and Spironolactone tablet and Torsemide Tablets and Spironolactone Tablets
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Jun 2025to 28 Feb 2026
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Subjects must fulfill all of the following criteria to be considered for inclusion into this study:
- Healthy human adult subjects within the age range of 18 to 45 years [both inclusive].
- Weight not less than 50 kg for male and 45 kg for female and BMI 18.50 to 29.99 kg/m2 [both inclusive].
- Willingness to provide written informed consent to participate in the study.
- Subjects should be non-smoker [defined as someone who has stopped smoking for a year before the date of screening] and should not be consuming tobacco containing products.
- Free of significant diseases or clinically significant abnormal findings during screening, medical history, physical examination, laboratory evaluations, 12-lead ECG, Chest X-ray [PA view].
Show all 10Show fewer
- Absence of disease markers of HIV 1 and 2, Hepatitis B and C and Syphilis.
- Subject should be literate.
- Male subjects must be using two acceptable methods of contraception (e.g., spermicidal gel plus condom) for the entire duration of the study, and upto the study completion visit. Subjects must refrain from fathering a child in the next two weeks following the last study drug administration or have undergone vasectomy (vasectomy must have been done more than 6 months prior to first dosing). Contraceptive usage requirement will be conveyed during the inform consent process. Subjects will be advised to follow effective method of contraception until 2 weeks after the last dose is given.
- Female subjects of childbearing potential must be using two acceptable methods of contraception, (e.g., intra-uterine device (IUD) plus condom, spermicidal gel plus condom, diaphragm plus condom, etc.), from the time of screening and for the duration of the study and for two weeks following the last study drug administration. Contraceptive usage requirement will be conveyed during the inform consent process (or) Postmenopausal women for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy have been performed).
Who cannot join
- Any of the following conditions are cause for exclusion from the study:
- History or presence of significant: cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, musculoskeletal, psychiatric disease/disorder.
- History or presence of significance:
- Asthma, urticaria, or other allergic-type reactions after taking Torsemide, Spironolactone or any other drug.
- Ulceration or history of gastric and/or duodenal ulcer. Stomach or intestinal bleeding. Jaundice in the past 6 months. Internal bleeding.
- Hypersensitivity or allergy to Torsemide, Spironolactone or any of the excipients.
Show all 26Show fewer
- History of alcohol or drug abuse in the past one year.
- Family history of bleeding disorders.
- History of difficulty in passing urine or emptying the bladder or of incontinence.
- Have donated 500 mL or more blood within 90 days before receiving the first dose of the study drug.
- Subjects who have participated in another clinical study in the past 3 months prior to commencement of this study.
- Any difficulty in the accessibility of forearm veins for cannulation or blood sampling and or difficulty with donating blood.
- Refuse to abstain from food for at least 10 h prior to dosing and for at least 4 h after dosing in each period.
- Refuse to abstain from fluid for at least 1 h before and 1 h after dosing in each period (except 240 ± 2 mL water given for dosing).
- Found positive during breath alcohol test done during period one check-in and inability to abstain from alcohol till the end of the study.
- Found positive during urine drug screening done prior to period one check-in.
- Found positive screening results for Hepatitis B, Hepatitis C, HIV, or Syphilis.
- History of difficulty in swallowing tablets.
- Received any medication [including over-the-counter products], herbal products for 14 days preceding the study.
- Use of enzyme-modifying drugs within 30 days prior to receiving the first dose of study medication.
- History of dehydration from diarrhea, vomiting, or any other reason within 24 hours prior to check-in of period one.
- Consumption of xanthine-containing food and beverages (chocolates, tea, coffee, or cola drinks) for at least 48 hours prior to check-in of period one.
- Consumption of grapefruit or its products within the 48 hours prior to check-in of period one.
- Female subjects are found to be positive during pregnancy tests done prior to period one check-in.
- Lactating females.
- Investigator/Physician feels that it is not in the subject's and/or study's best interest to enroll the subject.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Bioavailability and Bioequivalence (BA/BE) Study of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Human Subjects
To study intrasubject variability and steady-state pharmacokinetics of multiple-doses of Extended Release Torsemide and Spironolactone Fixed Dose Combination (FDC) tablets given together in healthy adult subjects.
Read the detailed description
To study intrasubject variability and steady-state pharmacokinetics of the multiple-doses of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) (12 mg ER Torsemide and 15 mg Spironolactone) tablet and 10 mg Torsemide and 25 mg Aldactone® (Spironolactone) tablets given together in healthy adult subjects. In addition, torsemide, sodium, potassium, and creatinine will be measured in the urine samples.
- Conditions
- Bioavailability Heathy Volunteers
- Being tested
- Torsemide and Spironolactone tablet, Torsemide Tablets and Spironolactone Tablets
- Keywords
- Torsemide, Spironolactone, Combination, Bioavailability
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Torsemide and Spironolactone tabletDrug
Fixed Dose Combination (FDC): (12 mg Extended Release (ER) Torsemide and 15 mg Spironolactone) tablet
Torsemide Tablets and Spironolactone TabletsDrug
10 mg Torsemide tablet and 25 mg Spironolactone tablet given together
| Study group | Role | What they receive |
|---|---|---|
| Arm 1 FDC | Active comparator | Fixed Dose Combination (FDC) 12 mg ER Torsemide and 15 mg Spironolactone tablet Receives: Drug: Torsemide and Spironolactone tablet; Drug: Torsemide Tablets and Spironolactone Tablets |
| Arm 2 (Torsemide tablets and Spironolactone tablets) | Active comparator | 10 mg Torsemide and 25 mg Spironolactone tablets given together Receives: Drug: Torsemide and Spironolactone tablet; Drug: Torsemide Tablets and Spironolactone Tablets |
What is being measured
The primary outcome is the main question the study is designed to answer.
Plasma (Blood) sample analysis of torsemide for Cmax
Measurement of torsemide in the blood for Cmax.
Measured: 24 hours
Plasma (Blood) sample analysis of torsemide for AUC
Measurement of torsemide in the blood for AUC.
Measured: 24 hours
Plasma (Blood) sample analysis of Spironolactone and Canrenone for Cmax
Measurement of Spironolactone and Canrenone in the blood (Active metabolite of spironolactone) for Cmax.
Measured: 24 hours
Plasma (Blood) sample analysis of AUC in the blood for Spironolactone and Canrenone
Measurement of Spironolactone and Canrenone (Active metabolite of spironolactone) for AUC.
Measured: 24 hours
Urine sample analysis to determine urinary excretion
Urine samples will be used to calculate urinary excretion at each timepoint and the total in 24 hours.
Measured: 24 hours
Urine sample analysis for torsemide secretion
Calculate percentage of torsemide recovered in the urine.
Measured: 24 hours
Urine sample analysis of torsemide for Rmax
Urinary torsemide excretion will be measured for Rmax.
Measured: 24 hours
Urine sample analysis for electrolytes
Electrolytes (sodium, potassium) will be measured to determine the percentage of drug recovered.
Measured: 24 hours
Urine sample analysis for creatinine
Urinary creatinine will be measured at each timepoint over 24 hours.
Measured: 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jul 2025
- Study start15 Jun 2025
- Primary completion28 Feb 2026
- Study completion28 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bioavailability Heathy VolunteersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Open label, randomized, two-period, two-sequence, balanced, multiple-dose crossover intrasubject variability and steady-state BA/BE study
- Masking
- None (open label)
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sarfez Pharmaceuticals, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Salim Shah, PhD, JD, Study director, Sarfez Pharmaceuticals, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07046975
- Sponsor's protocol ID
- SAR-HS-027-24
- Status last verified
- Mar 2026
- First submitted
- 6 Jun 2025
- Last updated
- 9 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: HIPAA
Study at a glance
From the registry record, last updated by the sponsor on 9 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bioavailability and Bioequivalence (BA/BE) Study of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Human Subjects
- ClinicalTrials.gov ID
- NCT07046975
- Acronym / sponsor ID
- SAR-HS-027-24
- Conditions
- Bioavailability Heathy Volunteers
- Keywords
- Torsemide, Spironolactone, Combination, Bioavailability
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 24 participants (actual)
- Lead sponsor
- Sarfez Pharmaceuticals, Inc.Industry (pharma, biotech, devices)
- Study start
- 15 Jun 2025 (actual)
- Primary completion
- 28 Feb 2026 (actual)
- Study completion
- 28 Feb 2026 (actual)
- First posted
- 2 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To study intrasubject variability and steady-state pharmacokinetics of multiple-doses of Extended Release Torsemide and Spironolactone Fixed Dose Combination (FDC) tablets given together in healthy adult subjects.
Detailed description
To study intrasubject variability and steady-state pharmacokinetics of the multiple-doses of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) (12 mg ER Torsemide and 15 mg Spironolactone) tablet and 10 mg Torsemide and 25 mg Aldactone® (Spironolactone) tablets given together in healthy adult subjects. In addition, torsemide, sodium, potassium, and creatinine will be measured in the urine samples.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Open label, randomized, two-period, two-sequence, balanced, multiple-dose crossover intrasubject variability and steady-state BA/BE study
| Arm | Type | Receives |
|---|---|---|
| Arm 1 FDC | Active comparator | Drug: Torsemide and Spironolactone tablet, Drug: Torsemide Tablets and Spironolactone TabletsFixed Dose Combination (FDC) 12 mg ER Torsemide and 15 mg Spironolactone tablet |
| Arm 2 (Torsemide tablets and Spironolactone tablets) | Active comparator | Drug: Torsemide and Spironolactone tablet, Drug: Torsemide Tablets and Spironolactone Tablets10 mg Torsemide and 25 mg Spironolactone tablets given together |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (10 listed)
- Subjects must fulfill all of the following criteria to be considered for inclusion into this study:
- Healthy human adult subjects within the age range of 18 to 45 years [both inclusive].
- Weight not less than 50 kg for male and 45 kg for female and BMI 18.50 to 29.99 kg/m2 [both inclusive].
- Willingness to provide written informed consent to participate in the study.
- Subjects should be non-smoker [defined as someone who has stopped smoking for a year before the date of screening] and should not be consuming tobacco containing products.
Key exclusion criteria (26 listed)
- History or presence of significant: cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, musculoskeletal, psychiatric disease/disorder.
- History or presence of significance:
- Asthma, urticaria, or other allergic-type reactions after taking Torsemide, Spironolactone or any other drug.
- Ulceration or history of gastric and/or duodenal ulcer. Stomach or intestinal bleeding. Jaundice in the past 6 months. Internal bleeding.
- Hypersensitivity or allergy to Torsemide, Spironolactone or any of the excipients.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Torsemide and Spironolactone tabletFixed Dose Combination (FDC): (12 mg Extended Release (ER) Torsemide and 15 mg Spironolactone) tablet | Drug | Arm 1 FDC, Arm 2 (Torsemide tablets and Spironolactone tablets) |
| Torsemide Tablets and Spironolactone Tablets10 mg Torsemide tablet and 25 mg Spironolactone tablet given together | Drug | Arm 1 FDC, Arm 2 (Torsemide tablets and Spironolactone tablets) |
Primary outcome
Plasma (Blood) sample analysis of torsemide for Cmax
Time frame: 24 hours
Measurement of torsemide in the blood for Cmax.
Plasma (Blood) sample analysis of torsemide for AUC
Time frame: 24 hours
Measurement of torsemide in the blood for AUC.
Plasma (Blood) sample analysis of Spironolactone and Canrenone for Cmax
Time frame: 24 hours
Measurement of Spironolactone and Canrenone in the blood (Active metabolite of spironolactone) for Cmax.
Plasma (Blood) sample analysis of AUC in the blood for Spironolactone and Canrenone
Time frame: 24 hours
Measurement of Spironolactone and Canrenone (Active metabolite of spironolactone) for AUC.
Urine sample analysis to determine urinary excretion
Time frame: 24 hours
Urine samples will be used to calculate urinary excretion at each timepoint and the total in 24 hours.
Urine sample analysis for torsemide secretion
Time frame: 24 hours
Calculate percentage of torsemide recovered in the urine.
Urine sample analysis of torsemide for Rmax
Time frame: 24 hours
Urinary torsemide excretion will be measured for Rmax.
Urine sample analysis for electrolytes
Time frame: 24 hours
Electrolytes (sodium, potassium) will be measured to determine the percentage of drug recovered.
Urine sample analysis for creatinine
Time frame: 24 hours
Urinary creatinine will be measured at each timepoint over 24 hours.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Mar 2026.
- Individual participant dataSharing planned: No. HIPAA
Related trials for Bioavailability Heathy Volunteers
Active, not recruiting
Bioavailability of Phlorotannins and Carotenoids Following the Intake of Crackers Fortified With Seaweed
Bioavailability Heathy Volunteers, Bioavailability and AUC
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Salim Shah, PhD, JD study director
Sarfez Pharmaceuticals, Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Torsemide and Spironolactone tablet and Torsemide Tablets and Spironolactone Tablets in people with Bioavailability Heathy Volunteers, run by Sarfez Pharmaceuticals, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Plasma (Blood) sample analysis of torsemide for Cmax (time frame: 24 hours). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Mar 2026.